The effects of polymorphisms in CYP2C19, ATP-binding cassette transporter B1, and paraoxonase-1 on clopidogrel treatment of Uygur patients following percutaneous coronary intervention-Reference-Cited by-同舟云学术

The effects of polymorphisms in CYP2C19, ATP-binding cassette transporter B1, and paraoxonase-1 on clopidogrel treatment of Uygur patients following percutaneous coronary intervention

Published:2021-06-23 Issue:11 Volume:77 Page:1679-1686
ISSN:0031-6970
Container-title:European Journal of Clinical Pharmacology
language:en
Short-container-title:Eur J Clin Pharmacol

Author:

Wang Tingting^ORCID,Li Hongjian,Wang Fengxia,Sun Li,Yu Luhai

Funder

Natural Science Foundation of Xinjiang Province

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pharmacology,General Medicine

Link

https://link.springer.com/content/pdf/10.1007/s00228-021-03176-z.pdf

Reference30 articles.

1. Levine GN, Bates ER, Bittl JA, Brindis RG, Fihn SD, Fleisher LA et al (2016) 2016 ACC/AHA Guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines: an update of the 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention, 2011 ACCF/AHA Guideline for coronary artery bypass graft surgery, 2012 ACC/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the diagnosis and management of patients with stable ischemic heart disease, 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction, 2014 AHA/ACC Guideline for the management of patients with non-ST-elevation acute coronary syndromes, and 2014 ACC/AHA Guideline on perioperative cardiovascular evaluation and management of patients undergoing noncardiac surgery. Circulation 134:e123–e155

2. Pereira NL, Rihal CS, So DYF, Rosenberg Y, Lennon RJ (2019) Clopidogrel pharmacogenetics. Circ Cardiovasc Interv 12(4):e007811

3. Sofi F, Giusti B, Marcucci R, Gori AM, Abbate R, Gensini GF (2011) Cytochrome P450 2C19*2 polymorphism and cardiovascular recurrences in patients taking clopidogrel: a meta-analysis. Pharmacogenomics J 11:199–206

4. Giusti B, Gori AM, Marcucci R, Saracini C, Vestrini A et al (2010) Determinants to optimize response to clopidogrel in acute coronary syndrome. Pharmgenomics Pers Med 3:33–50

5. Mega JL, Simon T, Collet JP, Anderson JL, Antman EM et al (2010) Reduced-function cyp2c19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for pci: a meta-analysis. JAMA 304:1821–1830

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Advances and Perspectives in methods for identifying high platelet reactivity;Heliyon;2023-12

2. The Cytochrome P450 2C19 Polymorphism Associated with Major Adverse Cardiovascular Events Risk in Kazak Patients Undergoing Percutaneous Coronary Intervention and Receiving Clopidogrel;Endocrine, Metabolic & Immune Disorders - Drug Targets;2023-02

3. Research Progress on Related Genes of Clopidogrel Resistance;Advances in Clinical Medicine;2023